As GLP-1 medications reshape the landscape of obesity and diabetes treatment, there’s a growing interest among researchers regarding their potential effects on cancer risk and outcomes. The American Association for Cancer Research’s recent Cancer Progress Report highlighted that obesity is a significant risk factor for various cancers.
Medications like semaglutides—Ozempic, Wegovy—and tirzepatides such as Mounjaro and Zepbound have garnered attention for their ability to promote substantial weight loss and enhance metabolic health. This has led many cancer researchers to explore whether these drugs might also play a role in cancer prevention.
The AACR report pointed out that while there are studies indicating that GLP-1 medications might lower the risk of specific cancers, the evidence is still somewhat inconsistent, suggesting a need for further research.
“Randomized clinical trials are essential … but such studies haven’t yet focused on cancer outcomes linked to GLP-1 RA use,” the report stated.
Dr. Sai Yendamuri, a thoracic surgeon from Roswell Park Comprehensive Cancer Center in New York, reinforced that obesity is a leading cancer contributor, second only to smoking. He mentioned that factors like alcohol consumption and poor nutrition are intertwined with obesity.
He posed an interesting question: if obesity is linked to cancer, could medications that reduce obesity actually have an impact? “There’s a lot of evidence suggesting that might be the case,” he noted.
For instance, studies involving patients undergoing metabolic surgery to combat obesity have shown a decrease in cancer instances among those individuals.
Following this, researchers have also been evaluating patients using GLP-1 receptor agonists like Ozempic. Comparisons made between cancer rates in these patients and those not on GLP-1s have revealed, in many studies, a lower cancer risk and higher survival rates in the former group.
However, it’s worth mentioning that not all studies confidently established this connection. Some even signaled an increased risk of certain cancers, including thyroid cancer, indicating a complicated relationship.
“This discrepancy arises from retrospective studies, which analyze existing data and try to find associations,” Yendamuri explained, adding that myriad variables can influence results.
His team has focused specifically on the connection between obesity and lung cancer, consistently finding that obesity heightens lung cancer risk. Yet, the definition and measurement of obesity vary, with researchers gradually shifting from the traditional BMI standard to more sophisticated assessments of body fat.
Yendamuri shared two significant findings. First, for patients undergoing lung cancer surgery while on GLP-1 receptor agonists, the recurrence rate appears to be lower. “We believe this could be tied to an improved immune response to cancer cells,” he stated.
Moreover, he noted that advanced-stage cancer patients receiving immunotherapy who were also on GLP-1s exhibited lower recurrence rates. His hypothesis, drawn from preclinical studies, is that GLP-1 medications directly affect cancer cells only minimally.
The variations in immune response could depend on the type of cancer, as some cancers, like melanoma, are significantly influenced by immune reactions.
Additionally, Yendamuri acknowledged that some of the benefits observed could indeed be related to weight loss achieved through these medications. “Not every patient will see substantial weight loss using GLP-1 receptor agonists, so future studies might investigate how benefits relate to weight loss,” he suggested.
The potential of these drugs may also extend to cancer prevention, depending on upcoming trial results, which leaves room for optimism regarding their role in cancer treatment strategies.
In closing, Dr. Yendamuri stressed the importance of continuous funding for organizations like the National Cancer Institute, which is integral in fostering cancer research and driving new advancements.
